Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Measureable disease according to the RECIST 1.1~* Previous radiotherapy is acceptable provided there are measurable, previously not irradiated lesions present~* Histologically or cytologically confirmed non-squamous non-small cell lung cancer~* Stage IIIB ineligible for curative therapy or stage IV disease~* ECOG Performance 0-2~* Adequate organ function defined as:~  1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy.~ 2. Total serum bilirubin ≤ 1.5 x ULN~ 3. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~ 4. Platelets ≥ 100 x 109/L~ 5. Creatinine clearance \> 45 ml/min~* Able to discontinue NSAIDs and ASA if reduced renal function~* All fertile patients should use safe contraception~* Written informed consent~Exclusion Criteria:~* prior systemic therapy for advanced non-small-cell lung cancer (including EGFR-TKI). Previous chemotherapy (e.g. adjuvant after surgery or for other cancer) is allowed if ≥ 3 months since the last course was administered.~* activating EGFR-mutation or ALK-translocation detected~* serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) that in the opinion of the investigator would compromise the patient's ability to complete the study or interfere with the evaluation of the efficacy and safety of the study treatment~* conditions - medical, social, psychological - which could prevent adequate information and follow-up~* clinically active cancer other than NSCLC~* known hypersensitivity or contraindications for the study drugs (vinorelbine, carboplatin, pemetrexed, B12, folate)~* pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- maintenance pemetrexed (Type: EXPERIMENTAL): maintenance pemetrexed immediately after induction chemotherapy
- pemetrexed at progression (Type: ACTIVE_COMPARATOR): observation and pemetrexed therapy at disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).